The data are early-stage and non-pivotal; the stock reaction will depend on market perception of ORR/DCR vs. safety trade-offs relative to approved PARP inhibitors. Key catalysts to watch: EIK1003 Phase 2 dose optimization completion (2H 2027), EIK1004 combination arm data (2H 2027), and EIK1005 monotherapy complete results (2H 2027).
Price Chart
Executive Summary
Eikon Therapeutics presented initial and updated clinical data from its PARP1-selective (EIK1003, EIK1004) and WRN helicase (EIK1005) programs at the 2026 ESMO Congress. The data show generally well-tolerated safety profiles and preliminary signs of antitumor activity across multiple cohorts, supporting continued clinical development. No financial results or guidance were provided in this filing.
Key Facts
- EIK1003 monotherapy (Cohort 1A) showed 14.3% ORR (7/49) in HRR-mutant tumors; 31.3% in PARP-naïve patients.
- EIK1003 + abiraterone (Cohort 1B) showed 20.8% ORR (5/24) in metastatic prostate cancer; DCR 83.3%.
- EIK1003 + paclitaxel (Cohort 1C) showed 26.4% ORR (14/53) in ovarian/breast cancer; 1 complete response.
- EIK1004 (CNS-penetrant PARP1i) showed 12.1% ORR (7/58) with minimal hematologic toxicity (Grade 3+ anemia/neutropenia 1.5% each).
- EIK1005 (WRN helicase inhibitor) showed stable disease in 6/8 (75%) MSI-H/dMMR patients; 1 PR in combination with pembrolizumab.
- Additional data readouts expected in 2027 for all three programs.
Financial Impact
No financial data disclosed; clinical-stage biotech with no approved products or reported revenue.
Risk Factors
- All three candidates are in Phase 1/2; high probability of clinical failure before registration trials.
- EIK1003 ORR in PARP-pretreated patients is low (6.1%), limiting addressable market.
- EIK1005 data are extremely early (n=11); stable disease is not a surrogate for durable response.
- Company has significant net losses and needs substantial additional funding per its own risk factors.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-429549 |
| Document: eikn-ex99_1.htm | 0001193125-26-429549 |
| Document: 0001193125-26-429549-index-headers.html | 0001193125-26-429549 |
| Document: 0001193125-26-429549-index.html | 0001193125-26-429549 |
| Document: 0001193125-26-429549.txt | 0001193125-26-429549 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $7.48 | awaiting T+20 | — | $7.26 (−2.94%) |
Oct 26, 2026 today | Press Release | $7.48 | awaiting T+20 | — | $7.26 (−2.94%) |
Oct 23, 2026 2d ago | 8-K | $8.01 | awaiting T+20 | — | $7.26 (−9.36%) |
Oct 7, 2026 18d ago | SC 13G/A | $7.54 | awaiting T+20 | — | $7.26 (−3.71%) |
Oct 2, 2026 23d ago | SC 13G/A | $7.33 | awaiting T+20 | — | $7.26 (−0.95%) |
Sep 22, 2026 4w ago | Institutional Cluster | $8.98 $8.18 | ▼ −8.91% | ▼ −8.35% | $7.26 (−19.15%) |
Sep 8, 2026 6w ago | Insider Buy | $10.73 $7.54 | ▼ −29.73% | ▼ −31.67% | $7.26 (−32.34%) |
Sep 3, 2026 7w ago | Press Release | $10.96 $8.04 | ▼ −26.64% | ▼ −25.52% | $7.26 (−33.76%) |
Aug 13, 2026 10w ago | 8-K | $11.05 $9.36 | ▼ −15.29% | ▼ −13.30% | $7.26 (−34.30%) |
Jul 20, 2026 14w ago | Press Release | $9.65 $10.47 | ▲ +8.50% | ▲ +4.38% | $7.26 (−24.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers